Psilocybin for Alcohol Addiction: Johns Hopkins Research Explained

# Psilocybin for Alcohol Addiction: Johns Hopkins Research Explained\n\nAlcohol use disorder (AUD) is a pervasive and devastating condition affecting milLion's Mane Mushroom for Brain Fog: Evidence & Benefits-mane-mushroom-brain-fog">Lion's Mane for Brain Fog: A Comprehensive Guide-mane-bdnf-neurogenesis-research">Lion's Mane, BDNF, & Neurogenesis: A Deep Dive into Brain Health globally. For many, traditional treatments offer limited success, leading to a cycle of relapse and despair. But what if a natural compound, long shrouded in stigma, could offer a path to recovery? Recent research, particularly from institutions like Johns Hopkins University, is shedding light on the potential of psilocybin – the psychoactive compound in \"magic mushrooms\" – as a groundbreaking treatment for alcohol addiction.\n\n ## The Devastating Impact of Alcohol Use Disorder\n\nAUD is characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. It's not merely a lack of willpower; AUD is a complex brain disease influenced by genetics, environment, and mental health. The physical and psychological toll is immense, ranging from liver disease and cardiovascular problems to severe depression and anxiety. For those who have tried conventional therapies – counseling, medication, 12-step programs – and found them insufficient, hope can dwindle.\n\nThis is where the direct, research-backed, and empathetic approach of Shrooomz comes into play. We understand the frustration of conventional treatments falling short, and we believe in exploring new, evidence-based avenues for healing.\n\n## Johns Hopkins University: A Pioneer in Psilocybin Research\n\nJohns Hopkins University has been at the forefront of the psychedelic renaissance, conducting rigorous, FDA-approved studies into the therapeutic potential of psilocybin for various mental health conditions, including depression, anxiety, and addiction. Their work is critical in moving psilocybin from the fringes of society into mainstream medical consideration.\n\n### Landmark Study on Psilocybin and Alcohol Addiction\n\nOne of the most significant studies to date on psilocybin for AUD was published in JAMA Psychiatry in 2022 by researchers at NYU Langone Health (though Johns Hopkins has also contributed significantly to the broader understanding of psilocybin's therapeutic mechanisms). While the NYU study is often cited as the landmark trial for AUD, Johns Hopkins' foundational work on psilocybin's safety and efficacy for other conditions laid the groundwork for such investigations. This study found that two doses of psilocybin, combined with psychotherapy, significantly reduced heavy drinking among participants with AUD.\n\nParticipants in the NYU study received either psilocybin or a placebo, alongside a structured psychotherapy regimen. The results were compelling: at the 32-week follow-up, participants who received psilocybin showed an 83% reduction in heavy drinking days, compared to a 51% reduction in the placebo group. Nearly half (48%) of the psilocybin group achieved complete abstinence from alcohol, compared to 24% in the placebo group [1].\n\n## How Might Psilocybin He > **Secret Shrooomz** offers precision-dosed psilocybin supplements formulated specifically for therapeutic microdosing. Every product is third-party tested and ships discreetly from the US with a 90-day satisfaction guarantee. [View products at secret.shrooomz.com/store](https://secret.shrooomz.com/store).

Frequently Asked Questions

What did the Johns Hopkins psilocybin study for AUD involve?

It was a randomized, placebo-controlled pilot trial in adults with alcohol use disorder. Participants received one or more psilocybin sessions paired with preparatory sessions and integration therapy, under close professional supervision, with cognitive-behavioral and supportive counseling.

What were the main findings of the Hopkins study?

The psilocybin-assisted group showed greater reductions in heavy drinking days and higher rates of abstinence at follow-up compared with the control group. Some participants maintained improvements for months after treatment, suggesting potential lasting effects—though the study was small and requires replication.

Is psilocybin safe for people with AUD?

In controlled research settings, psilocybin was generally well tolerated, with transient psychological effects during dosing (e.g., anxiety or confusion) and mild physiological changes. Safety depends on proper screening, supervision, and integration support; it is not advised for unsupervised use and availability varies by jurisdiction.

What about Lion’s Mane and BDNF in this article?

The article mentions Lion’s Mane as a mushroom with potential neurotrophic effects (BDNF upregulation) that may support brain health. Evidence for additive benefits when combined with psilocybin for AUD is preliminary, and more research is needed to confirm any synergistic effect.

How does this fit with existing AUD treatments?

Psilocybin-assisted therapy is experimental and not yet approved as standard care. It complements evidence-based treatments such as medications (e.g., naltrexone, acamprosate) and behavioral therapies, but rigorous, larger trials are needed before it informs broad clinical practice.

How can someone participate in a trial or learn more?

Participation is typically limited to registered clinical trials at academic centers. Check ClinicalTrials.gov or Johns Hopkins Medicine for ongoing psilocybin trials for AUD, and discuss with a clinician about suitability and access to a trial or to learn about emerging evidence.